121 related articles for article (PubMed ID: 17695408)
1. Desmoid-type fibromatosis.
Bertucci F; Gonçalves A; Viens P; Monges G; Dubreuil P
J Neurosurg; 2007 Aug; 107(2):473-5; author reply 475. PubMed ID: 17695408
[No Abstract] [Full Text] [Related]
2. Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status.
Seinfeld J; Kleinschmidt-Demasters BK; Tayal S; Lillehei KO
J Neurosurg; 2006 May; 104(5):749-56. PubMed ID: 16703880
[TBL] [Abstract][Full Text] [Related]
3. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
Ravaioli A; Nicoletti S; Tamburini E; Papi M
J Cancer Res Clin Oncol; 2009 Feb; 135(2):325-6. PubMed ID: 18825412
[TBL] [Abstract][Full Text] [Related]
4. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
Ioannou M; Demertzis N; Iakovidou I; Kottakis S
Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
[TBL] [Abstract][Full Text] [Related]
5. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.
Wcislo G; Szarlej-Wcislo K; Szczylik C
J Cancer Res Clin Oncol; 2007 Aug; 133(8):533-8. PubMed ID: 17453242
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
[No Abstract] [Full Text] [Related]
7. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
8. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
[TBL] [Abstract][Full Text] [Related]
9. A new KIT gene mutation in thymic cancer and a promising response to imatinib.
Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249
[No Abstract] [Full Text] [Related]
10. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.
Dufresne A; Alberti L; Brahmi M; Kabani S; Philippon H; Pérol D; Blay JY
BMC Cancer; 2014 Aug; 14():632. PubMed ID: 25174682
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; Basi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marrè MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M
Blood; 2005 Jan; 105(2):904; author reply 905. PubMed ID: 15632213
[No Abstract] [Full Text] [Related]
12. Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
[No Abstract] [Full Text] [Related]
13. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
[No Abstract] [Full Text] [Related]
14. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.
Dufresne A; Bertucci F; Penel N; Le Cesne A; Bui B; Tubiana-Hulin M; Ray-Coquard I; Cupissol D; Chevreau C; Perol D; Goncalves A; Jimenez M; Bringuier PP; Blay JY
Br J Cancer; 2010 Aug; 103(4):482-5. PubMed ID: 20664593
[TBL] [Abstract][Full Text] [Related]
15. Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report.
Dao A; Benchakroun N; Jabir H; Taleb A; Bouchbika Z; Tawfiq N; Jouhadi H; Sahraoui S; Benider A
J Med Case Rep; 2014 Dec; 8():416. PubMed ID: 25488584
[TBL] [Abstract][Full Text] [Related]
16. Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma.
Silvestris N; Parra HS; Angelini F; Di Cosimo S; D'Aprile M; Santoro A
Tumori; 2005; 91(1):103. PubMed ID: 15850018
[No Abstract] [Full Text] [Related]
17. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
18. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Tamborini E; Negri T; Miselli F; Lagonigro MS; Pricl S; Pilotti S
J Natl Cancer Inst; 2006 Nov; 98(21):1583-4. PubMed ID: 17077361
[No Abstract] [Full Text] [Related]
19. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Strauss LG; Hohenberger P
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1876-82. PubMed ID: 20559633
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
